

MINUTES

EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS “SOPHARMA” AD

SOFIA, 4 August 2023, 11:00 a.m. (UTC 8:00 a.m.)

ISIN BG11SOSOBT18
Event identification code: SFAEGM04082023

I. CONSTITUTING THE GENERAL MEETING OF SHAREHOLDERS

Today, **4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.)**, at the headquarters of the Company in Sofia, at 5 Lachezar Stanchev Str., Ground floor, Sopharma Business Towers Shopping Center, Sopharma Event Center, an Extraordinary General Meeting of the shareholders of “Sopharma” AD was held, which was attended by shareholders and their proxies, according to the attached list. Under the conditions of art. 115 “b”, para 5 and 6 of LPOS and art. 16 “a”, para 2 of the Articles of Association of the Company, shareholders have also exercised their right to vote at the Extraordinary General Meeting according to the lists and minutes prepared by the Commission for verification of the quorum and the submitted capital. The total number of shareholders / proxies present at the meeting and of the shareholders who voted by correspondence and the number of shares held or represented by them is specified in the attached protocol for verification of the quorum and the represented capital.

The Executive Director of “Sopharma” AD, Mr. Ognian Donev, welcomed the shareholders and suggested that the General Meeting elect a Commission for Verification of the Quorum and Represented Capital, which will also disclose the data of the completed registration of the shareholders and their proxies for participation in the General Meeting as well as from the statements for voting by correspondence received in the company within the term under art. 115 “b”, para 6 declarations for voting by correspondence in the present General Meeting.

Mrs. Pelagia Viatcheva was proposed for Chairperson of the Commission and for Secretary: Nikolai Georgiev.

Other suggestions were not made, which is why Mr. Donev invited the attending shareholders and proxies to vote for the election of Quorum and Presented Capital Verification Commission in its proposed composition.

Results of the vote: *The General Meeting unanimously voted for a Quorum and Presented Capital Verification Commission with the following members: Chairperson - Pelagia Viatcheva and Secretary –Nikolai Georgiev.*

Mrs. Viatcheva presented to the shareholders a protocol with the Commission's findings of the verification after the registration of the shareholders and their proxies was completed, namely:

Registered capital – **134 797 899** dematerialized registered shares, each with a nominal value of BGN 1 (one) and with the right to 1 (one) vote at the General Meeting of Shareholders.

Number of treasury shares of “Sopharma” AD – **13 479 188** Pursuant to art. 187a, para. 3 of the Commercial Law, the rights for the treasury shares are not exercised until their transfer.

Total number of shares with voting rights that can participate in the Extraordinary General Meeting of Shareholders convened on 4 August 2023 – **121 318 711**.

Results of the registration:

This document is a translation of the Minutes of the EGM of “Sopharma” AD held on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.).

At the time of completion of the registration, shareholders and proxies of shareholders are registered to participate in the Extraordinary General Meeting of Shareholders as follows:

Personally, are represented **36 809 502 shares or 27.31%** of the registered capital.

Through a proxy are represented **47 663 885 shares or 35.36%** of the registered capital.

Through correspondence before the date of the General Meeting, shareholders holding a total number of **9 215 222 shares** representing **6.84%** of the registered capital. According to art. 115 "b", para 6 of the LPOS, the shares of the persons who voted by correspondence shall be taken into account in determining the quorum, and the voting shall be noted in the minutes of the General meeting.

Total represented shares at the General Meeting, including shares, the voting right of which is exercised by correspondence – 93 688 609 representing **69.50%** of the registered capital of the Company.

For the registration of the shareholders and proxies present at the General Meeting, a list of the shareholders registered for participation in the General Meeting and their proxies has been drawn up, on which each person has personally signed after certifying his/her identity/representative authority before the person of registration. The list shall be certified by the Chairperson and the Secretary of the Extraordinary General Meeting on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.).

For the statements for voting by correspondence received within the term under art. 115 "b", para 6 the Chairperson and Secretary of the Commission for verification of the quorum and represented capital created a list, which certifies the date of receipt of the statements and their compliance with the rules for voting by correspondence, specified in the invitation for the General Meeting. The list is signed by the Chairperson and the Secretaries of the Commission for verification of the quorum and the represented capital and should be certified by the Chairperson and Secretary of the Extraordinary General Meeting on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.).

On behalf of the Quorum Verification Commission and the capital presented, Mrs. Viatcheva confirmed to the General Meeting that:

- All represented shares are entitled to one vote at the General Meeting;
- The number of the shares represented in person, by proxy and by correspondence does not exceed the number of shares for the respective shareholder according to the Book of shareholders of the Company as at 21 July 2023 for the number of shares with voting rights at the Extraordinary General Meeting of Shareholders of “Sopharma” AD convened on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.);
- The statements for exercising the right to vote in the General meeting by correspondence received within the term under art. 115 "b", para 6 meet the requirements of the company for voting by correspondence specified in the invitation.

Mrs. Viatcheva provided a Protocol signed by the members of the Commission for Verification of the Quorum and the Represented Capital as well as an original List of Shareholders, proxies and List of shareholders who voted by correspondence for the Extraordinary General Meeting of Shareholders of “Sopharma” AD, held on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.).

Mr. Donev proposed to the General Meeting to vote for the adoption of the Commission's protocol on the verification of the quorum and the represented capital.

Results from the voting:

	Valid votes			Votes „For“		Votes „Against“		Votes „Abstained“	
	number	% from the capital represented in the room	% from the registered capital	number	% from the capital represented in the room	number	% from the capital represented in the room	number	% from the capital represented in the room
Total	84 473 387	100.00%	69.50%	84 473 387	100.00%	0	0.00%	0	0.00%
- of them through correspondence	0	0.00%	0.00%	0	0.00%	0	0.00%	0	0.00%
- of them through proxy	47 663 885	56.43%	35.36%	47 663 885	56.43%	0	0.00%	0	0.00%

The report of the Commission for verification of the quorum and the represented capital was adopted unanimously by the represented shares.

There are no objections to the way of voting and the announced results.

ELECTION OF MANAGEMENT OF THE GENERAL MEETING:

1. Proposal made for the management of the General Meeting by the Bord of Directors included in the invitation:

For Chairperson - Pelagia Viacheva

For Secretary – Yanita Mincheva

For Teller – Denitza Radeva.

Results from the voting:

	Valid votes			Votes „For“		Votes „Against“		Votes „Abstained“	
	number	% from the capital represented	% from the registered capital	number	% from the capital represented	number	% from the capital represented	number	% from the capital represented
Total	93 688 609	100.00%	69.50%	0	0.00%	84 473 387	90.16%	0	0.00%
- of them through correspondence	9 215 222	9.84%	6.84%	9 215 222	9.84%	0	0.00%	0	0.00%
- of them through proxy	47 663 885	50.87%	35.36%	0	0.00%	47 663 885	50.87%	0	0.00%

There are no objections to the way of voting and the announced results.

2. Proposal made for the management of the General Meeting by the Executive director:

For Chairperson - Pelagia Viacheva

This document is a translation of the Minutes of the EGM of “Sopharma” AD held on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.).

For Secretary – Nikolai Georgiev
For Teller – Yanita Mincheva

Results from the voting:

	Valid votes			Votes „For“		Votes „Against“		Votes „Abstained“	
	number	% from the capital represented in the room	% from the registered capital	number	% from the capital represented in the room	number	% from the capital represented in the room	number	% from the capital represented in the room
Total	84 473 387	100.00%	69.50%	84 473 387	100.00%	0	0.00%	0	0.00%
- of them through correspondence	0	0.00%	0.00%	0	0.00%	0	0.00%	0	0.00%
- of them through proxy	47 663 885	56.43%	35.36%	47 663 885	56.43%	0	0.00%	0	0.00%

The General Meeting elected the proposed by the Executive Director persons for Chairperson, Secretary and Tellers of the Extraordinary General Meeting, which takes place in Sofia on 4 August 2023.

There are no objections to the way of voting and the announced results.

FINDINGS OF THE CHAIRPERSON AND THE SECRETARY OF THE MEETING:

After opening the session of the General Meeting, the Chairperson and the Secretary notified the shareholders about the following circumstances:

1. The invitation was announced in the Commercial Register with registration from July 3, 2023 with number 20230703151109, as well as on the web site of the Company. The announcement was within the statutory period under art. 223, para 5 of the Commercial Law and in compliance with the requirements of the Law on Public Offering of Securities for notifications to the Financial Supervision Commission, the Bulgarian Stock Exchange and the Public regarding the convening of the General Meeting of Shareholders, the agenda and the draft decisions.
2. The Chairperson and the Secretary received an original List of Shareholders and their proxyholders and List of shareholders who voted by correspondence for the Extraordinary General Meeting of Shareholders of “Sopharma” AD, held on 4 August 2023, which they certified with their signatures.
3. For representation of shareholders in front of the General Meeting are presented 8 proxies, which correspond to the form and content of the requirements of the Law on Public Offering of Securities and of the Rules for Voting through proxy adopted by the Company 6 proxies were submitted electronically within the time limit specified in the invitation, namely by the end of the business day preceding the day of the General meeting.
4. By the order and under the conditions of art. 16a of the Articles of Association of the Company and art. 115 “b”, para 6 of LPOS, their right to vote by correspondence have been exercised by 5 shareholders with a total of 9 215 222 shares.
5. For participation in the General Meeting are presented 93 688 609 shares, which represents 69.50% of the capital of the Company, of which 36 809 502 - presented in person, 47 663 885 - presented through a proxy and 9 215 222 - by correspondence. There is a quorum

provided for in the Law and the Articles of Association of the company and the General Meeting may be held regularly and adopt valid decisions on the announced agenda.

6. The following members of the Board of Directors are present at the General Meeting:

- Ognian Ivanov Donev – Chairperson of the Board of Directors and Executive Director;
- Bissera Lazarova – member of the Board of Directors.

7. The following persons have expressed a desire to attend the meeting as guests:

Teodor Anadoliev, Vania Ivanova, Weselin Radoichev, Dimityr Georgiev and Milen Markov

The chairman put to the vote the presence of the guests.

Results from the voting:

	Valid votes			Votes „For“		Votes „Against“		Votes „Abstained“	
	number	% from the capital represented in the room	% from the registered capital	number	% from the capital represented in the room	number	% from the capital represented in the room	number	% from the capital represented in the room
Total	84 473 387	100.00%	69.50%	84 473 387	100.00%	0	0.00%	0	0.00%
- of them through correspondence	0	0.00%	0.00%	0	0.00%	0	0.00%	0	0.00%
- of them through proxy	47 663 885	56.43%	35.36%	47 663 885	56.43%	0	0.00%	0	0.00%

The General Meeting accepts the listed persons to attend the General Meeting of Shareholders as guests.

There are no objections to the way of voting and the announced results.

The Agenda of the General Meeting announced in the Commercial Register and the proposals for decisions on the items on the agenda are as follows:

- 1. Adoption of a decision for transformation by merger of "Biopharm-engineering" AD into Sopharma AD; Draft decision:** *The EGM transforms "Sopharma" AD through the merger of "Biopharm-engineering" AD. As a result of the merger, all the assets of "Biopharm-engineering" AD will be transferred to "Sopharma" AD under the conditions of general succession;*
- 2. Approval of the Agreement for transformation through the merger of "Biopharm-engineering" AD into "Sopharma" AD, concluded on 23.01.2023 and of Additional Agreement № 1 of 21.03.2023 to it; Draft decision:** *The EGM approves the Agreement for conversion through the merger of "Biopharm-engineering" AD into "Sopharma" AD, concluded on 23.01.2023, Additional Agreement № 1 dated 21.03.2023 and Additional Agreement № 2 dated 15.05.2023 to it ("Conversion Agreement");*
- 3. Approval of the Report of the Board of Directors of "Sopharma" AD under Art. 262i of the Commercial Code to the Company's shareholders regarding the transformation by merger of "Biopharm-engineering" AD into "Sopharma" AD; Draft decision:** *The EGM approves the Report of the Board of Directors of Sopharma AD to the Company's shareholders regarding the transformation through the merger of "Biopharm-engineering" AD into "Sopharma" AD;*

This document is a translation of the Minutes of the EGM of "Sopharma" AD held on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.).

4. **Approval of the Examiner's Report under Art. 262m of the Commercial Companies Code regarding the transformation by merger of "Biopharm-engineering" AD into "Sopharma" AD; Draft decision:** *The EGM approves the Auditor's Report under Art. 262m of the Commercial Code regarding the transformation by merger of "Biopharm-engineering" AD into "Sopharma" AD;*
5. **Approval of the Audit Committee Statute as proposed by the Board of Directors; Draft decision:** *The EGM approves the Audit Committee status as proposed by the Board of Directors;*
6. **Approval of decision for acquisition of own shares; Draft decision:** *The general meeting of shareholders, on the basis of art. 187b of the Commercial Law and art. 111, para. 5 of the LPOS, adopts a decision to buy back own shares from the capital of the company under the following conditions: not more than 3% for each calendar year; term of the redemption - no longer than 18 (eighteen) months; minimum redemption price – not lower than the nominal value of one share of the company's capital; maximum redemption price BGN 6.50 per share; The General Meeting authorizes the Board of Directors of the company to determine all other parameters of the buyback and to carry out the necessary factual and legal actions to implement the decision of the General Meeting of Shareholders;*
7. **Miscellaneous.**

At the General Meeting of Shareholders not all the voting shares issued by the Company are represented, therefore, and **on the grounds of art. 231, para. 1 of the Commercial Law the examination of other issues outside the announced agenda is not possible.**

Following the announcement of the invitation in the Commercial Register, additional issues are not included under the terms of art. 223a of the Commerce Law to the announced agenda for today's General Meeting of shareholders, as well as other proposals for decisions on the announced issues on the agenda in the sense of art. 118, para. 2, item 4 of LPOS.

Shareholders registered for participation in the Extraordinary General Meeting on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.) are entitled, in compliance with the law, to make substantive proposals for decisions on any matter on the agenda to terminate the debate on this issue before voting of a decision on it by the General Meeting.

During the General Meeting, the shareholders of the Company have the right to ask questions on all items of the agenda, as well as questions about the economic and financial status and the commercial activity of the Company, whether these are related to the agenda.

The materials related to the items of the announced agenda of the General Meeting are at disposal of the shareholders from the moment of announcing the invitation for the General Meeting in the Commercial Register at the Registry Agency. The same are available and in the hall where the General Meeting is held. In electronic form, the materials for the General Meeting are also available on the official website of the Company, including at the time of holding the Extraordinary General Meeting of Shareholders.

II. DEBATES AND DECISIONS ON THE AGENDA

On item 1 of the agenda:

Adoption of a decision for transformation by merger of "Biopharm-engineering" AD into "Sopharma" AD.

The Chairperson read the proposal of the Board of Directors for a decision on this item on the agenda, namely: *The EGM transforms "Sopharma" AD through the merger of "Biopharm-engineering" AD. As a result of the merger, all the assets of "Biopharm-engineering" AD will be transferred to "Sopharma" AD under the conditions of general succession.*

Until the discussions on this item of the agenda have been concluded, no other proposals for decisions have been made in accordance with the provision of art. 115, para 2, item 6 of the Law on Public Offering of Securities.

The Chairperson announced the end of the deliberations and initiated the voting on the proposal of the Board of Directors by announcing that the decision should be taken by a special 3/4 majority of the represented shares of the Company's capital.

Results from the voting:

	Valid votes			Votes „For“		Votes „Against“		Votes „Abstained“	
	number	% from the capital represented	% from the registered capital	number	% from the capital represented	number	% from the capital represented	number	% from the capital represented
Total	93 688 609	100.00%	69.50%	93 688 609	100.00%	0	0.00%	0	0.00%
- of them through correspondence	9 215 222	9.84%	6.84%	9 215 222	9.84%	0	0.00%	0	0.00%
- of them through proxy	47 663 885	50.87%	35.36%	47 663 885	50.87%	0	0.00%	0	0.00%

Under these results the General Meeting took the following DECISION:

The EGM transforms "Sopharma" AD through the merger of "Biopharm-engineering" AD. As a result of the merger, all the assets of "Biopharm-engineering" AD will be transferred to "Sopharma" AD under the conditions of general succession.

The decision was taken with a majority as per the Commercial Law and the Articles of Association of the Company.

No objections to the manner of voting and the results were received.

On item 2 of the agenda:

Approval of the Agreement for transformation through the merger of "Biopharm-engineering" AD into "Sopharma" AD, concluded on 23.01.2023 and of Additional Agreement № 1 of 21.03.2023 to it.

The Chairperson read the proposal of the Board of Directors for a decision on this item on the agenda, namely: *The EGM approves the Agreement for conversion through the merger of "Biopharm-engineering" AD into "Sopharma" AD, concluded on 23.01.2023, Additional Agreement № 1 dated 21.03.2023 and Additional Agreement № 2 dated 15.05.2023 to it ("Conversion Agreement").*

Until the discussions on this item of the agenda have been concluded, no other proposals for decisions have been made in accordance with the provision of art. 115, para 2, item 6 of the Law on Public Offering of Securities.

The Chairperson announced the end of the deliberations and initiated the voting on the proposal of the Board of Directors by announcing that the decision should be taken by a special 3/4 majority of the represented shares of the Company's capital.

Results from the voting:

	Valid votes		Votes „For“	Votes „Against“	Votes „Abstained“

	number	% from the capital represented	% from the registered capital	number	% from the capital represented	number	% from the capital represented	number	% from the capital represented
Total	93 688 609	100.00%	69.50%	93 688 609	100.00%	0	0.00%	0	0.00%
- of them through correspondence	9 215 222	9.84%	6.84%	9 215 222	9.84%	0	0.00%	0	0.00%
- of them through proxy	47 663 885	50.87%	35.36%	47 663 885	50.87%	0	0.00%	0	0.00%

Under these results the General Meeting took the following DECISION:

The EGM approves the Agreement for conversion through the merger of "Biopharm-engineering" AD into "Sopharma" AD, concluded on 23.01.2023, Additional Agreement № 1 dated 21.03.2023 and Additional Agreement № 2 dated 15.05.2023 to it ("Conversion Agreement").

The decision was taken with a majority as per the Commercial Law and the Articles of Association of the Company.

No objections to the manner of voting and the results were received.

On item 3 of the agenda:

Approval of the Report of the Board of Directors of "Sopharma" AD under Art. 262i of the Commercial Code to the Company's shareholders regarding the transformation by merger of "Biopharm-engineering" AD into "Sopharma" AD.

The Chairperson read the proposal of the Board of Directors for a decision on this item on the agenda, namely: *The EGM approves the Report of the Board of Directors of Sopharma AD to the Company's shareholders regarding the transformation through the merger of "Biopharm-engineering" AD into "Sopharma" AD.*

Until the discussions on this item of the agenda have been concluded, no other proposals for decisions have been made in accordance with the provision of art. 115, para 2, item 6 of the Law on Public Offering of Securities.

The Chairperson announced the end of the deliberations and initiated the voting on the proposal of the Board of Directors by announcing that the decision should be taken by a special 3/4 majority of the represented shares of the Company's capital.

Results from the voting:

	Valid votes			Votes „For“		Votes „Against“		Votes „Abstained“	
	number	% from the capital represented	% from the registered capital	number	% from the capital represented	number	% from the capital represented	number	% from the capital represented
Total	93 688 609	100.00%	69.50%	93 688 609	100.00%	0	0.00%	0	0.00%
- of them through correspondence	9 215 222	9.84%	6.84%	9 215 222	9.84%	0	0.00%	0	0.00%

This document is a translation of the Minutes of the EGM of "Sopharma" AD held on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.).

- of them through proxy	47 663 885	50.87%	35.36%	47 663 885	50.87%	0	0.00%	0	0.00%
-------------------------	------------	--------	--------	------------	--------	---	-------	---	-------

Under these results the General Meeting took the following DECISION:

The EGM approves the Report of the Board of Directors of Sopharma AD to the Company's shareholders regarding the transformation through the merger of "Biopharm-engineering" AD into "Sopharma" AD.

The decision was taken with a majority as per the Commercial Law and the Articles of Association of the Company.

No objections to the manner of voting and the results were received.

On item 4 of the agenda:

Approval of the Examiner's Report under Art. 262m of the Commercial Companies Code regarding the transformation by merger of "Biopharm-engineering" AD into "Sopharma" AD.

The Chairperson read the proposal of the Board of Directors for a decision on this item on the agenda, namely: *The EGM approves the Auditor's Report under Art. 262m of the Commercial Code regarding the transformation by merger of "Biopharm-engineering" AD into "Sopharma" AD.*

Until the discussions on this item of the agenda have been concluded, no other proposals for decisions have been made in accordance with the provision of art. 115, para 2, item 6 of the Law on Public Offering of Securities.

The Chairperson announced the end of the deliberations and initiated the voting on the proposal of the Board of Directors by announcing that the decision should be taken by a special 3/4 majority of the represented shares of the Company's capital.

Results from the voting:

	Valid votes			Votes „For“		Votes „Against“		Votes „Abstained“	
	number	% from the capital represented	% from the registered capital	number	% from the capital represented	number	% from the capital represented	number	% from the capital represented
Total	93 688 609	100.00%	69.50%	93 688 609	100.00%	0	0.00%	0	0.00%
- of them through correspondence	9 215 222	9.84%	6.84%	9 215 222	9.84%	0	0.00%	0	0.00%
- of them through proxy	47 663 885	50.87%	35.36%	47 663 885	50.87%	0	0.00%	0	0.00%

Under these results the General Meeting took the following DECISION:

The EGM approves the Auditor's Report under Art. 262m of the Commercial Code regarding the transformation by merger of "Biopharm-engineering" AD into "Sopharma" AD.

This document is a translation of the Minutes of the EGM of "Sopharma" AD held on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.).

The decision was taken with a majority as per the Commercial Law and the Articles of Association of the Company.

No objections to the manner of voting and the results were received.

On item 5 of the agenda:

Approval of the Audit Committee Statute as proposed by the Board of Directors.

The Chairperson read the proposal of the Board of Directors for a decision on this item on the agenda, namely: *The EGM approves the Audit Committee status as proposed by the Board of Directors.*

Until the discussions on this item of the agenda have been concluded, no other proposals for decisions have been made in accordance with the provision of art. 115, para 2, item 6 of the Law on Public Offering of Securities.

The Chairperson announced the end of the deliberations and initiated the voting on the proposal of the Board of Directors by announcing that the decision should be taken by a simple majority of the represented shares of the Company's capital.

Results from the voting:

	Valid votes			Votes „For“		Votes „Against“		Votes „Abstained“	
	number	% from the capital represented	% from the registered capital	number	% from the capital represented	number	% from the capital represented	number	% from the capital represented
Total	93 688 609	100.00%	69.50%	93 688 609	100.00%	0	0.00%	0	0.00%
- of them through correspondence	9 215 222	9.84%	6.84%	9 215 222	9.84%	0	0.00%	0	0.00%
- of them through proxy	47 663 885	50.87%	35.36%	47 663 885	50.87%	0	0.00%	0	0.00%

Under these results the General Meeting took the following DECISION:

The EGM approves the Audit Committee status as proposed by the Board of Directors.

The decision was taken with a majority as per the Commercial Law and the Articles of Association of the Company.

No objections to the manner of voting and the results were received.

On item 6 of the agenda:

Approval of decision for acquisition of own shares.

The Chairperson read the proposal of the Board of Directors for a decision on this item on the agenda, namely: *The general meeting of shareholders, on the basis of art. 187b of the Commercial Law and art. 111, para. 5 of the LPOS, adopts a decision to buy back own shares from the capital of the company under the following conditions: not more than 3% for each calendar year; term of the redemption - no longer than 18 (eighteen) months; minimum redemption price – not lower than the nominal value of one share of the company's capital; maximum redemption price BGN 6.50 per share; The General Meeting authorizes the Board of Directors of the company to determine all other parameters of the buyback and to carry out the necessary factual and legal actions to implement the decision of the General Meeting of Shareholders.*

Until the discussions on this item of the agenda have been concluded, no other proposals for decisions have been made in accordance with the provision of art. 115, para 2, item 6 of the Law on Public Offering of Securities.

The Chairperson announced the end of the deliberations and initiated the voting on the proposal of the Board of Directors by announcing that the decision should be taken by a special 2/3 majority of the represented shares of the Company's capital.

Results from the voting:

	Valid votes			Votes „For“		Votes „Against“		Votes „Abstained“	
	number	% from the capital represented	% from the registered capital	number	% from the capital represented	number	% from the capital represented	number	% from the capital represented
Total	93 688 609	100.00%	69.50%	63 134 322	67.39%	0	0.00%	30 554 287	32.61%
- of them through correspondence	9 215 222	9.84%	6.84%	9 215 222	9.84%	0	0.00%	0	0
- of them through proxy	47 663 885	50.87%	35.36%	47 663 885	50.87%	0	0.00%	0	0

Under these results the General Meeting took the following DECISION:

The general meeting of shareholders, on the basis of art. 187b of the Commercial Law and art. 111, para. 5 of the LPOS, adopts a decision to buy back own shares from the capital of the company under the following conditions: not more than 3% for each calendar year; term of the redemption - no longer than 18 (eighteen) months; minimum redemption price – not lower than the nominal value of one share of the company's capital; maximum redemption price BGN 6.50 per share; The General Meeting authorizes the Board of Directors of the company to determine all other parameters of the buyback and to carry out the necessary factual and legal actions to implement the decision of the General Meeting of Shareholders.

The decision was taken with a majority as per the Commercial Law and the Articles of Association of the Company.

No objections to the manner of voting and the results were received.

On item 7 of the agenda:

This document is a translation of the Minutes of the EGM of “Sopharma” AD held on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.).

Miscellaneous.

There are no suggestions on this point and there is no vote.

The agenda of the Extraordinary General Meeting of Shareholders of “Sopharma” AD was exhausted, therefore the Chairperson closed the meeting.

The present minutes were prepared and signed in three identical copies. An integral part of these minutes is: The Commission's Quorum Verification Protocol and the represented capital, the list of the shareholders and shareholder representatives with the number of shares owned and represented by them, List of shareholders who voted by correspondence for the Extraordinary General Meeting of Shareholders of “Sopharma” AD, held on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.). Written powers of attorney to represent shareholders at the General Meeting; Certificates for current status of the shareholders and proxies - legal entities, Declarations for voting by correspondence as well as Materials on the convening of the Extraordinary General Meeting, held on 4 August 2023 at 11:00 a.m. (UTC 8:00 a.m.) in Sofia.

CHAIRPERSON OF THE GM:

/Signature/
/Pelagia Viatcheva/

SECRETARY OF THE GM:

/Signature/
/Nikolai Georgiev/

TELLER:

/Signature/
/Yanita Mincheva/